List of Excipients in Branded Drug NICOTINE POLACRILEX GUM

« Back to Dashboard

Generic Drugs Containing NICOTINE POLACRILEX GUM

Company	Ingredient	NDC	Excipient
Rite Aid Corporation	nicotine polacrilex	11822-3322	ACACIA
Rite Aid Corporation	nicotine polacrilex	11822-3322	ACESULFAME POTASSIUM
Rite Aid Corporation	nicotine polacrilex	11822-3322	CARNAUBA WAX
Rite Aid Corporation	nicotine polacrilex	11822-3322	FD&C BLUE NO. 2
Rite Aid Corporation	nicotine polacrilex	11822-3322	FD&C RED NO. 40
Rite Aid Corporation	nicotine polacrilex	11822-3322	FD&C YELLOW NO. 6
Rite Aid Corporation	nicotine polacrilex	11822-3322	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in NICOTINE POLACRILEX GUM?

# Of NDCs	Excipient
1	ACACIA
2	ACESULFAME POTASSIUM
1	CALCIUM CARBONATE
2	CARNAUBA WAX
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 2
1	FD&C RED NO. 40

Nicotine Polacrilex Gum Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 27, 2026

Nicotine polacrilex gum is a mature over-the-counter smoking-cessation product with limited patent protection and broad formulation flexibility. The active is a nicotine-resin complex released through chewing, not a conventional nicotine salt. Commercial differentiation depends on taste, chewing texture, nicotine-release control, packaging, dosage range, and regulatory execution rather than composition-of-matter exclusivity.

The strongest opportunities are private-label products, sugar-free and low-sensory formulations, improved mouthfeel, faster or more consistent nicotine release, pediatric-resistant packaging, and regional products aligned with local smoking-cessation regulations. The main technical barrier is demonstrating comparable nicotine release and exposure while preserving the product’s characteristic chew-and-park administration.

What is nicotine polacrilex gum?

Nicotine polacrilex gum is an oral nicotine-replacement therapy in which nicotine is complexed with a cation-exchange resin. The resin moderates nicotine release during chewing. Salivary nicotine is absorbed primarily through the buccal mucosa, while swallowed nicotine contributes less because of gastrointestinal and hepatic metabolism.

Common strengths are:

Product strength	Nominal nicotine content	Typical use
2 mg	2 mg nicotine	Lower-dependence users or step-down therapy
4 mg	4 mg nicotine	Higher-dependence users, often including early-morning smokers

The product is generally chewed intermittently and then parked between the cheek and gum. Continuous chewing can increase swallowing of nicotine and produce gastrointestinal or throat-related adverse effects. U.S. labeling includes a structured 12-week cessation regimen, with use frequency reduced over time (FDA, 2024a).

Nicotine polacrilex is the active pharmaceutical ingredient, not an inactive excipient. The commercial gum also contains a gum base, sweeteners, plasticizers or humectants, buffering agents, flavors, and processing aids.

What excipients are used in nicotine polacrilex gum?

The excipient system has four main functions: mechanical chewability, nicotine release, taste control, and product stability.

Typical excipient categories

Excipient category	Representative materials	Primary function
Gum base	Proprietary elastomer-resin mixtures	Chewability, residence in the mouth, product structure
Bulk sweeteners	Sorbitol, mannitol, xylitol, maltitol	Sweetness, bulk, cooling sensation, tablet or gum mass
High-intensity sweeteners	Acesulfame potassium, sucralose, saccharin derivatives	Taste enhancement at low loading
Buffering agents	Sodium carbonate, sodium bicarbonate, potassium carbonate	Salivary pH control and nicotine liberation
Humectants and plasticizers	Glycerol, propylene glycol, related materials	Softness, flexibility, moisture control
Flavors	Mint, spearmint, fruit, menthol-type systems	Nicotine bitterness and irritation masking
Coating materials	Polyols, film-forming agents, waxes or related systems	Handling, taste onset, moisture protection
Processing aids	Talc, waxes, flow aids, approved lubricants	Manufacturing and surface properties

Commercial labels show variation in sweetener, flavor, coating, and buffering systems. Nicorette products, for example, use a gum base with polyol sweeteners, sodium carbonate, glycerol, flavoring, and an intense sweetener; generic products may use different flavor and coating systems while retaining comparable performance (DailyMed, 2024a; DailyMed, 2024b).

The formulation must avoid excipient choices that change nicotine release excessively. A stronger buffer can increase nicotine liberation, but it can also increase local irritation, bitterness, and early nicotine exposure. A softer gum may improve consumer acceptance but can alter chewing behavior and release kinetics.

How should an excipient strategy be designed for nicotine polacrilex gum?

The formulation target should be defined as a quality-by-design profile rather than as a simple ingredient match to the reference product.

1. Control nicotine release through resin and buffer interaction

Nicotine polacrilex release depends on:

• Resin particle size and crosslinking characteristics
• Nicotine loading and ionic binding
• Gum-base composition
• Buffer capacity
• Salivary pH
• Chewing intensity and duration
• Moisture content
• Storage temperature and humidity

The formulation should establish a reproducible release curve under a validated chewing-gum dissolution method. A product that releases nicotine too slowly may have weak craving control. A product that releases it too quickly may increase throat irritation, nausea, hiccups, and swallowing-related exposure.

2. Optimize mouthfeel without changing dose delivery

Consumers generally evaluate nicotine gum through:

• Initial flavor impact
• Nicotine irritation
• Chew resistance
• Stickiness
• Crumbling
• Residual bitterness
• Duration of acceptable taste
• Ease of parking between the cheek and gum

Gum-base selection is therefore a commercial and technical lever. A lower-elasticity base may improve initial chewability but create excessive tack. A harder base can support prolonged use but may be less acceptable to older smokers or users with dental limitations.

3. Use sugar-free systems strategically

Sugar-free products are commercially standard and reduce dental concerns. Sorbitol is widely used but can cause gastrointestinal effects at high total daily intake. Xylitol and erythritol can provide cooling and different sweetness profiles, but they can change gum texture and manufacturing behavior.

A differentiated product could use a mixed-polyol system to balance:

• Softness
• Hygroscopicity
• Cooling effect
• Sweetness persistence
• Gastrointestinal tolerability
• Water activity
• Stability under heat and humidity

The use of novel excipients creates a regulatory burden. Established compendial excipients with prior oral use generally reduce review risk.

4. Treat flavor as a clinical-performance variable

Flavor is not merely a branding element. It affects chewing duration, salivation, perceived nicotine intensity, and adherence. Mint and menthol systems dominate the category because they mask bitterness and provide a cooling effect. Fruit flavors may expand use among consumers who dislike medicinal mint but can be more difficult to balance against nicotine irritation.

An attractive development program would test flavor intensity against actual chewing behavior rather than relying only on sensory panels. Excessive flavor can encourage continuous chewing, which may increase adverse effects.

5. Build packaging around stability and misuse control

Nicotine products require moisture-protective packaging. Key packaging variables include:

• Individual blister cavities
• Child-resistant outer packs
• Unit-dose foil protection
• Tamper evidence
• High-barrier films
• Temperature and humidity protection
• Clear separation of 2 mg and 4 mg strengths

Packaging can be a source of product differentiation because nicotine gum is often carried and used outside the home. A pocket-sized, discreet, child-resistant format can compete with lozenges, pouches, and transdermal patches.

What FDA regulatory status applies to nicotine polacrilex gum?

Nicotine gum is an FDA-regulated over-the-counter smoking-deterrent drug. The U.S. regulatory framework includes the FDA’s smoking-cessation OTC monograph and the relevant provisions in 21 C.F.R. Part 341. Nicotine is recognized for use in chewing gum at 2 mg and 4 mg strengths when the applicable conditions are met (FDA, 2022; 21 C.F.R. § 341.40).

A manufacturer generally has two strategic routes:

Route	Commercial use	Main regulatory issue
OTC monograph compliance	Products meeting monograph conditions	Formula, labeling, manufacturing, and quality must fit monograph requirements
NDA or approved-product pathway	Branded, novel, or otherwise non-monograph products	Greater clinical and CMC burden, but more flexibility for differentiated claims

A material departure from monograph conditions may require an FDA application. Novel delivery mechanisms, unusual nicotine-release profiles, nonstandard strengths, or unsupported cessation claims can move a product outside the simplest monograph pathway.

What is the Orange Book status of nicotine polacrilex gum?

The Orange Book is primarily relevant to approved prescription and certain approved nonprescription drug applications. Standard OTC monograph nicotine gum does not depend on an Orange Book patent listing in the same way as an NDA product.

The commercial consequence is significant: a new manufacturer operating within the OTC monograph does not normally need to overcome a listed patent through a Paragraph IV certification. The product instead requires compliance with the monograph, current good manufacturing practice, labeling rules, and applicable FDA requirements.

A branded product that relies on an approved NDA could have application-specific listing and exclusivity issues, but the core nicotine polacrilex gum category has no active composition-of-matter barrier comparable to a recently launched prescription drug (FDA, 2024b).

When does nicotine polacrilex gum lose exclusivity?

The principal nicotine gum patents and early product protections expired years ago. Nicorette and related nicotine-replacement products have been commercially available for decades, and the basic nicotine-polacrilex gum concept is no longer protected by a meaningful blocking patent estate.

Current exclusivity is therefore based mainly on:

• Brand recognition
• Retail placement
• Consumer loyalty
• Flavor and sensory performance
• Manufacturing know-how
• Packaging design
• Regulatory compliance
• Distribution agreements
• Trade dress and trademarks

A manufacturer should still conduct a current patent and trademark search before launch. Later patents may cover a specific gum base, coating, manufacturing process, release profile, packaging configuration, or combination product. Those rights are unlikely to block ordinary monograph-compliant nicotine gum across the market but may affect a narrowly designed formulation.

Are there Paragraph IV challenges for nicotine polacrilex gum?

Paragraph IV litigation is not the central entry mechanism for ordinary nicotine gum.

A Paragraph IV certification applies to an abbreviated application that references patents listed for a reference drug in the Orange Book. A monograph-compliant OTC product generally proceeds without certifying against an Orange Book patent estate. An NDA-based product could present a different analysis if it has listed patents.

The likely market-entry paths are:

1. Monograph-compliant OTC launch.
2. Private-label supply under a contract manufacturing agreement.
3. Application-based approval for a novel formulation or claim.
4. Acquisition or licensing of an existing branded or regional product.

The litigation risk is more likely to involve formulation patents, trade dress, trademark rights, product liability, manufacturing contracts, or advertising claims than a classic Paragraph IV challenge.

What patent rights protect nicotine polacrilex gum today?

The core active ingredient and basic dosage form have little practical exclusivity value. Potentially relevant rights fall into narrower categories:

Formulation patents

These may address:

• Specific gum-base compositions
• Particular nicotine-resin particle sizes
• Controlled-release combinations
• Taste-masking systems
• Buffer systems
• Coated resin particles
• Low-irritation formulations
• Polyol combinations
• Moisture-control systems

Manufacturing patents

Potential claims may cover:

• Resin loading
• Mixing order
• Temperature-controlled incorporation of nicotine polacrilex
• Extrusion or rolling conditions
• Coating processes
• Reduced-nicotine-loss processing
• Uniformity testing

Method-of-use patents

Potential method claims could cover:

• Combination use with patches or lozenges
• Specific dosing schedules
• Use in particular populations
• Cessation protocols
• Nicotine titration regimens

Method-of-use protection is difficult to monetize in an OTC category unless the claim is supported by a differentiated product and effective consumer communication.

Trademark and trade dress

For a mature product, trademarks and trade dress can be more commercially relevant than patents. Brand names, logos, packaging appearance, and distinctive flavor positioning can limit copying even when the underlying formulation is open.

How strong is the patent estate for nicotine polacrilex gum?

The patent estate is weak for the basic product and potentially moderate for narrow technical improvements.

Asset type	Current protection outlook	Commercial impact
Nicotine polacrilex as a basic active	Largely expired or nonblocking	Low
Standard 2 mg and 4 mg gum	Mature category	Low
Conventional gum base and sweeteners	Limited patent value	Low
Specific controlled-release formulation	Possible narrow protection	Moderate
Novel taste-masking system	Possible but design-around likely	Moderate
Manufacturing process	Potentially valuable if difficult to reproduce	Moderate
Packaging and child-resistant design	Protectable in limited cases	Low to moderate
Brand and trade dress	Often commercially important	High for established brands

The practical strength of a new patent depends on whether the claimed formulation produces measurable advantages in nicotine release, tolerability, stability, adherence, or manufacturing yield. Broad claims covering ordinary gum ingredients are vulnerable to prior-art and obviousness challenges.

What commercial opportunities exist for nicotine polacrilex gum?

Private-label and retailer brands

Retailers can offer 2 mg and 4 mg products with lower marketing costs than a national brand. The product is suitable for store brands because the category is familiar, stable, and generally purchased through pharmacies, mass retailers, supermarkets, and e-commerce.

The main requirements are dependable supply, acceptable taste, compliant labeling, and strong packaging controls.

Regional and emerging-market expansion

Nicotine gum is suitable for countries with established smoking-cessation programs and limited access to prescription cessation products. Regulatory classification varies by jurisdiction. Some countries treat nicotine gum as a pharmacy medicine; others allow general-sale status.

A regional strategy should account for:

• Permitted nicotine strength
• Local labeling language
• Smoking-cessation claims
• Pharmacist involvement
• Import controls
• Nicotine excise treatment
• Advertising restrictions
• Stability-zone requirements

Combination cessation products

Nicotine gum can be paired with a nicotine patch or used in a structured step-down program. Combination therapy is already recognized in clinical practice and labeling contexts, but a commercial product should not make unsupported efficacy claims. Combination packaging, adherence kits, and pharmacist-supported programs may offer better margins than a stand-alone commodity gum.

Premium sensory products

A premium product could differentiate through:

• Lower initial irritation
• Longer-lasting flavor
• Reduced bitterness
• Improved chew texture
• Discreet packaging
• Multiple flavor options
• A clear transition from 4 mg to 2 mg use

The product must preserve nicotine delivery while improving acceptability. Sensory improvements that reduce use persistence or alter release can weaken the product’s clinical utility.

Adjacency to nicotine pouches

Nicotine pouches compete for oral nicotine consumers but do not offer the same regulatory positioning or cessation-use pattern in every market. Nicotine gum can be positioned as a regulated smoking-cessation product with standardized dosing, established instructions, and broad pharmacy acceptance.

A company with nicotine-pouch manufacturing capabilities may have relevant pouching, flavor, and moisture-control expertise, but pouch technology does not automatically translate to gum production. Gum requires specialized compounding, extrusion, rolling, cutting, coating, and stability controls.

What manufacturing and intellectual-property barriers affect entry?

The active ingredient is available from qualified suppliers, but the finished product is not a simple direct-compression formulation. Manufacturing barriers include:

• Uniform distribution of nicotine polacrilex
• Temperature control during mixing
• Prevention of nicotine loss or migration
• Consistent gum-base plasticity
• Control of residual moisture
• Flavor retention
• Strength-to-strength segregation
• Chewing-gum release testing
• Packaging-line containment and reconciliation

Supplier qualification is important because differences in resin particle size, nicotine loading, water content, and impurity profile can affect product performance. A change in nicotine polacrilex supplier may require comparative release, stability, and quality studies.

The most defensible know-how may sit in process parameters rather than patent claims. A manufacturer that achieves consistent release, low batch variability, and good sensory performance can create a meaningful cost and quality advantage without relying on broad patent exclusivity.

How does nicotine polacrilex gum compare with other nicotine-replacement products?

Product	Main advantage	Main limitation	Competitive position
Nicotine gum	User-controlled dosing and oral behavioral replacement	Taste, chewing technique, gastrointestinal effects	Strong mature OTC category
Nicotine lozenge	No chewing required; discreet	Mouth irritation and dissolution variability	Direct oral substitute
Nicotine patch	Simple once-daily dosing	Slower dose adjustment; skin reactions	Complementary product
Nicotine nasal spray	Rapid delivery	Prescription or restricted access in some markets	Niche
Nicotine inhaler	Hand-to-mouth ritual	Device and cost complexity	Smaller market
Nicotine pouch	Discreet and flavor-led	Regulatory and cessation-positioning differences	Adjacent competitor

Nicotine gum retains a commercial advantage where consumers want rapid, user-controlled dosing without a device. Its main weakness is sensory experience, which creates the clearest formulation opportunity.

What generic launch risks exist?

Generic and private-label launch risks are moderate from a regulatory perspective and higher from a product-performance perspective.

The main risks are:

• Failure to match nicotine release
• Inadequate dose uniformity
• Poor flavor acceptance
• Excessive gum hardness or stickiness
• Stability failure under heat and humidity
• Incomplete monograph compliance
• Packaging that is not sufficiently child-resistant
• Consumer confusion between 2 mg and 4 mg strengths
• Claims that exceed permitted cessation language
• Supply interruptions for nicotine polacrilex or specialized gum base

The absence of a strong blocking patent estate lowers legal entry risk. It does not eliminate the need for formulation development, chewing-gum testing, stability work, and manufacturing validation.

What is the revenue exposure and commercial outlook?

The category is commercially mature, and branded revenue is concentrated among established nicotine-replacement companies and retailer-controlled private labels. Stand-alone sales of nicotine polacrilex gum are not consistently disclosed by public companies, so precise product-level revenue estimates are not reliable.

The strongest revenue models are likely to be:

• High-volume private label
• Contract manufacturing
• Regional pharmacy distribution
• Bundled cessation programs
• Premium sensory formulations
• Multi-strength and multi-flavor portfolios

Margin pressure is likely for standard 2 mg and 4 mg products. A differentiated product needs either lower manufacturing cost, stronger retail placement, superior consumer retention, or a defensible formulation or process advantage.

Key Takeaways

• Nicotine polacrilex gum is an established OTC smoking-cessation product with limited basic patent protection.
• The active ingredient is a nicotine-resin complex; it should not be treated as an excipient.
• Excipient selection directly affects nicotine release, bitterness, irritation, chewing behavior, and stability.
• Buffer strength, gum-base composition, polyol system, and flavor architecture are the main formulation levers.
• Ordinary monograph-compliant products generally do not face a classic Paragraph IV entry dispute.
• Formulation, manufacturing, packaging, trademark, and trade-dress rights are more relevant than composition-of-matter patents.
• Private-label, regional, premium sensory, and combination-therapy packaging are the clearest commercial opportunities.
• The central technical requirement is reproducible nicotine release under realistic chewing conditions.
• Supplier qualification and process know-how can create a stronger commercial barrier than broad patent claims.
• Nicotine gum competes directly with lozenges and indirectly with patches, inhalers, and nicotine pouches.

FAQs

Is nicotine polacrilex the same as nicotine?

No. Nicotine polacrilex is a complex of nicotine with a polacrilex ion-exchange resin. The resin controls release during chewing, while nicotine is the pharmacologically active component.

Can a company launch a generic nicotine gum without a Paragraph IV filing?

A company may generally pursue an OTC monograph-compliant product without a Paragraph IV certification. An NDA-based product referencing an approved drug application may require a different patent and regulatory analysis.

Which excipient has the greatest effect on nicotine release?

Buffering agents often have a substantial effect because they influence salivary pH and nicotine liberation. Gum-base composition, resin properties, moisture, and chewing conditions also materially affect release.

Are nicotine gum formulation patents commercially valuable?

They can be valuable when they claim a measurable improvement in release, irritation, stability, taste, or manufacturing efficiency. Broad claims covering conventional gum ingredients are more vulnerable to design-around and validity challenges.

Can nicotine polacrilex gum be marketed as a nicotine-pouch alternative?

It can be positioned as a regulated oral nicotine-cessation product, but marketing claims must comply with applicable FDA or local requirements. The product should be differentiated through standardized dosing, cessation labeling, and clinical-use instructions rather than unsupported comparative claims.

References

1. DailyMed. (2024a). Nicorette nicotine polacrilex chewing gum: Drug label. U.S. National Library of Medicine.

2. DailyMed. (2024b). Nicotine polacrilex chewing gum: Drug label. U.S. National Library of Medicine.

3. Food and Drug Administration. (2022). OTC monograph M006: Smoking cessation drug products. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2024a). Nicotine polacrilex gum labeling and directions for use. U.S. Department of Health and Human Services.

5. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

6. United States Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Government Publishing Office.